Medical needs in the treatment of psychotic disorders

Handbook of Experimental Pharmacology

Volumn 212, Issue , 2012, Pages 165-185

  Leweke, F Markus ^a   Odorfer, Thorsten M ^a   Bumb, J Malte ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Compliance; First and second generation antipsychotics; Medical needs; Patient adherence; Quality of life; Schizophrenia; Side effects

Indexed keywords

AMISULPRIDE; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ASENAPINE; CHLORPROMAZINE; CLOZAPINE; FIRST GENERATION ANTIPSYCHOTIC; HALOPERIDOL; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; PLACEBO; QUETIAPINE; RISPERIDONE; SECOND GENERATION ANTIPSYCHOTIC; SERTINDOLE; SULPIRIDE; TRIFLUOPERAZINE; UNCLASSIFIED DRUG; ZIPRASIDONE;

ABDOMINAL PAIN; AGRANULOCYTOSIS; AKATHISIA; AKINESIA; ANTICHOLINERGIC SYNDROME; ARTICLE; BITTER TASTE; BLURRED VISION; CLINICAL TRIAL (TOPIC); CONSTIPATION; DIZZINESS; DROWSINESS; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSKINESIA; DYSPEPSIA; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; HUMAN; HYPERGLYCEMIA; HYPERKINESIA; HYPERLIPIDEMIA; HYPERSALIVATION; HYPESTHESIA; HYPOTENSION; INSOMNIA; LOW DRUG DOSE; META ANALYSIS (TOPIC); MUSCLE HYPERTONIA; MUSCLE HYPOTONIA; NAUSEA; OFF LABEL DRUG USE; ORTHOSTATIC HYPOTENSION; ORTHOSTATIC INTOLERANCE; PATIENT COMPLIANCE; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PSYCHOSIS; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCHIZOPHRENIA; SEDATION; SEIZURE; SEXUAL DYSFUNCTION; SIDE EFFECT; SINUS TACHYCARDIA; SOMNOLENCE; TARDIVE DYSKINESIA; TEMPERATURE; TREMOR; WEIGHT CHANGE; WEIGHT GAIN; XEROSTOMIA; REVIEW;

ANTIPSYCHOTIC AGENTS; HUMANS; OFF-LABEL USE; PSYCHOTIC DISORDERS;

EID: 84870177594     PISSN: 01712004     EISSN: 18650325     Source Type: Book Series    
DOI: 10.1007/978-3-642-25761-2_7     Document Type: Article

References (103)

1. Adams CE, Awad G, Rathbone J, Thornley B (2007) Chlorpromazine versus placebo for schizophrenia Cochrane Database Syst Rev (2):CD000284
2. Ardizzone I, Nardecchia F, Marconi A, Carratelli TI, Ferrara M (2010) Antipsychotic medication in adolescents suffering from schizophrenia: a meta-analysis of randomized controlled trials. Psychopharmacol Bull 43:45-66
3. Arif SA, Mitchell MM (2011) Iloperidone: a new drug for the treatment of schizophrenia. AJHP 68:301-308
4. Ascher-Svanum H, Zhu B, Faries DE, Lacro JP, Dolder CR, Peng X (2008) Adherence and persistence to typical and atypical antipsychotics in the naturalistic treatment of patients with schizophrenia. Patient Prefer Adherence 2:67-77
5. Asenjo Lobos C, Komossa K, Rummel-Kluge C, Hunger H, Schmid F, Schwarz S, Leucht S (2010) Clozapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev (11):CD006633
6. Atmaca M, Kuloglu M, Tezcan E, Gecici O, Ustundag B (2003) Weight gain, serum leptin and triglyceride levels in patients with schizophrenia on antipsychotic treatment with quetiapine, olanzapine and haloperidol. Schizophr Res 60:99-100 (Pubitemid 36015794)
7. Ban TA (2007) Fifty years chlorpromazine: a historical perspective. Neuropsychiatr Dis Treat 3:495-500 (Pubitemid 350028014)
8. Basile VS, Masellis M, Potkin SG, Kennedy JL (2002) Pharmacogenomics in schizophrenia: the quest for individualized therapy. Hum Mol Genet 11:2517-2530 (Pubitemid 35174716)
9. Beaumont G (2000) Antipsychotics - the future of schizophrenia treatment. Curr Med Res Opin 16:37-42 (Pubitemid 30107751)
10. Bebbington PE (1995) The content and context of compliance. Int Clin Psychopharmacol 9(Suppl 5):41-50
11. Bespalov A, Klein C, Behl B, Gross G, Schoemaker H (2012) Development of disease-modifying treatment of schizophrenia. In: Geyer MA, Gross G (eds) Novel antischizophrenia treatments, vol 213, Handbook of Experimental Pharmacology. Springer, Heidelberg
12. Beitinger R, Lin J, Kissling W, Leucht S (2008) Comparative remission rates of schizophrenic patients using various remission criteria. Prog Neuropsychopharmacol Biol Psychiatry 32:1643-1651
13. Bostwick JR, Guthrie SK, Ellingrod VL (2009) Antipsychotic-induced hyperprolactinemia. Pharmacotherapy 29:64-73
14. Breier A, Berg PH, Thakore JH, Naber D, Gattaz WF, Cavazzoni P, Walker DJ, Roychowdhury SM, Kane JM (2005) Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia. Am J Psychiatry 162:1879-1887 (Pubitemid 41428617)
15. Buchanan RW, Panagides J, Zhao J, Phiri P, den Hollander W, Ha X, Kouassi A, Alphs L, Schooler N, Szegedi A, Cazorla P (2012) Asenapine versus olanzapine in people with persistent negative symptoms of schizophrenia. J Clin Psychopharmacol 32:36-45
16. Burlon M (2007) Pharmakotherapy der Schizophrenie - "State of the art". NeuroTransmitter 5:59-70
17. Ceskova E, Svestka J (1993) Double-blind comparison of risperidone and haloperidol in schizophrenic and schizoaffective psychoses. Pharmacopsychiatry 26:121-124
18. Chan HY, Lin WW, Lin SK, Hwang TJ, Su TP, Chiang SC, Hwu HG (2007) Efficacy and safety of aripiprazole in the acute treatment of schizophrenia in Chinese patients with risperidone as an active control: a randomized trial. J Clin Psychiatry 68:29-36
19. Citrome L (2010) Iloperidone redux: a dissection of the Drug Approval Package for this newly commercialised second-generation antipsychotic. Int J Clin Pract 64:707-718
20. Collins PY, Patel V, Joestl SS, March D, Insel TR, Daar AS, Anderson W, Dhansay MA, Phillips A, Shurin S, Walport M, Ewart W, Savill SJ, Bordin IA, Costello EJ, Durkin M, Fairburn C, Glass RI, Hall W, Huang Y, Hyman SE, Jamison K, Kaaya S, Kapur S, Kleinman A, Ogunniyi A, Otero-Ojeda A, Poo MM, Ravindranath V, Sahakian BJ, Saxena S, Singer PA, Stein DJ (2011) Grand challenges in global mental health. Nature 475:27-30
21. Copolov DL, Link CG, Kowalcyk B (2000) A multicentre, double-blind, randomized comparison of quetiapine (ICI 204,636, 'Seroquel') and haloperidol in schizophrenia. Psychol Med 30:95-105 (Pubitemid 30099122)
22. Correll CU (2011) What are we looking for in new antipsychotics? J Clin Psychiatry 72 (Suppl 1):9-13
23. Correll CU, Leucht S, Kane JM (2004) Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry 161:414-425 (Pubitemid 38326094)
24. Costa AM, Lima MS, Mari Jde J (2006) A systematic review on clinical management of antipsychotic-induced sexual dysfunction in schizophrenia. Sao Paulo medical journal = Revista paulista de medicina 124:291-297 (Pubitemid 46210378)
25. Daniel DG, Zimbroff DL, Potkin SG, Reeves KR, Harrigan EP, Lakshminarayanan M (1999) Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group. Neuropsychopharmacology 20:491-505 (Pubitemid 29123876)
26. De Hert M, Detraux J, van Winkel R, Yu W, Correll CU (2011) Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol 8:114-126
27. Dolder CR, Lacro JP, Dunn LB, Jeste DV (2002) Antipsychotic medication adherence: is there a difference between typical and atypical agents? Am J Psychiatry 159:103-108 (Pubitemid 41070734)
28. Dollfus S, Olivier V, Chabot B, Deal C, Perrin E (2005) Olanzapine versus risperidone in the treatment of post-psychotic depression in schizophrenic patients. Schizophr Res 78:157-159 (Pubitemid 41254019)
29. Essali A, Al-Haj Haasan N, Li C, Rathbone J (2009) Clozapine versus typical neuroleptic medication for schizophrenia. Cochrane Database Syst Rev (1):CD000059
30. Fenton WS, Blyler CR, Heinssen RK (1997) Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophr Bull 23:637-651 (Pubitemid 27485972)
31. Freedman R (2003) Schizophrenia. N Engl J Med 349:1738-1749 (Pubitemid 37315012)
32. Green AI, Burgess ES, Dawson R, Zimmet SV, Strous RD (2003) Alcohol and cannabis use in schizophrenia: effects of clozapine vs. risperidone. Schizophr Res 60:81-85 (Pubitemid 36015790)
33. Gross G, Drescher K (2012) The role of dopamine D3 receptors in antipsychotic activity and cognitive functions. In: Geyer M, Gross G (eds) Novel antischizophrenia treatments, vol 213, Handbook of Experimental Pharmacology. Springer, Heidelberg
34. Harrison G, Hopper K, Craig T, Laska E, Siegel C, Wanderling J, Dube KC, Ganev K, Heiden W, Holmberg SK, Janca A, Lee PW, Leon CA, Malhotra S, Marsella AJ, Nakane Y, Sartorius N, Shen Y, Skoda C, Thara R, Tsirkin SJ, Varma VK, Walsh D, Wiersma D (2001) Recovery from psychotic illness: a 15- and 25-year international follow-up study. Br J Psychiatry 178:506-517 (Pubitemid 32531743)
35. Heal DJ, Gosden J, Jackson HC, Cheetham SC, Smith SL (2012) Metabolic consequences of antipsychotic therapy - preclinical and clinical perspectives on diabetes, diabetic ketoacidosis and obesity. In: Gross G, Geyer MA (eds) Current antipsychotics, vol 212, Handbook of Experimental Pharmacology. Springer, Heidelberg
36. Heck AH, Haffmans PM, de Groot IW, Hoencamp E (2000) Risperidone versus haloperidol in psychotic patients with disturbing neuroleptic-induced extrapyramidal symptoms: a doubleblind, multi-center trial. Schizophr Res 46:97-105
37. Hellewell JS (2002) Quetiapine: a well-tolerated and effective atypical antipsychotic. Hosp Med 63:600-603
38. Heres S, Davis J, Maino K, Jetzinger E, Kissling W, Leucht S (2006) Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics. Am J Psychiatry 163:185-194 (Pubitemid 44480836)
39. Hiemke C, Pfuhlmann B (2012) Interactions and monitoring of antipsychotic drugs. In: Gross G, Geyer MA (eds) Current antipsychotics, vol 212, Handbook of Experimental Pharmacology. Springer, Heidelberg
40. Honer WG, Procyshyn RM, Chen EY, MacEwan GW, Barr AM (2009) A translational research approach to poor treatment response in patients with schizophrenia: clozapine-antipsychotic polypharmacy. J Psychiatry Neurosci 34:433-442
41. Hori H, Noguchi H, Hashimoto R, Nakabayashi T, Omori M, Takahashi S, Tsukue R, Anami K, Hirabayashi N, Harada S, Saitoh O, Iwase M, Kajimoto O, Takeda M, Okabe S, Kunugi H (2006) Antipsychotic medication and cognitive function in schizophrenia. Schizophr Res 86:138-146 (Pubitemid 44234045)
42. Insel TR (2010) Rethinking schizophrenia. Nature 468:187-193
43. Jayaram MB, Hosalli PM, Stroup TS (2007) Risperidone versus olanzapine for treatment of schizophrenia. Schizophr Bull 33:1274-1276 (Pubitemid 350022780)
44. Jones PB, Barnes TR, Davies L, Dunn G, Lloyd H, Hayhurst KP, Murray RM, Markwick A, Lewis SW (2006) Randomized controlled trial of the effect on Quality of Life of second-vs firstgeneration antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 63:1079-1087 (Pubitemid 44498387)
45. Joy CB, Adams CE, Lawrie SM (2006) Halopridol versus placebo for schizophrenia. Cochrane Database Syst Rev 18(4):CD003082
46. Kaddurah-Daouk R, McEvoy J, Baillie RA, Lee D, Yao JK, Doraiswamy PM, Krishnan KR (2007) Metabolomic mapping of atypical antipsychotic effects in schizophrenia. Mol Psychiatry 12:934-945 (Pubitemid 47482696)
47. Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IP, Gheorghe MD, Rybakowski JK, Galderisi S, Libiger J, Hummer M, Dollfus S, Lopez-Ibor JJ, Hranov LG, Gaebel W, Peuskens J, Lindefors N, Riecher-Rossler A, Grobbee DE (2008) Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 371:1085-1097 (Pubitemid 351418005)
48. Kane JM, Correll CU (2010) Past and present progress in the pharmacologic treatment of schizophrenia. J Clin Psychiatry 71:1115-1124
49. Kane JM, Mackle M, Snow-Adami L, Zhao J, Szegedi A, Panagides J (2011) A randomized placebo-controlled trial of asenapine for the prevention of relapse of schizophrenia after long-term treatment. J Clin Psychiatry 72:349-355
50. Keck P Jr, Buffenstein A, Ferguson J, Feighner J, Jaffe W, Harrigan EP, Morrissey MR (1998) Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial. Psychopharmacology 140:173-184 (Pubitemid 28538477)
51. Kern RS, Green MF, Nuechterlein KH, Deng BH (2004) NIMH-MATRICS survey on assessment of neurocognition in schizophrenia. Schizophr Res 72:11-19 (Pubitemid 39452901)
52. Komossa K, Rummel-Kluge C, Schmid F, Hunger H, Schwarz S, El-Sayeh HG, Kissling W, Leucht S (2009) Aripiprazole versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev: (4) CD006569
53. Komossa K, Rummel-Kluge C, Hunger H, Schmid F, Schwarz S, Duggan L, Kissling W, Leucht S (2010a) Olanzapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev (3):CD006654
54. Komossa K, Rummel-Kluge C, Schmid F, Hunger H, Schwarz S, Srisurapanont M, Kissling W, Leucht S (2010b) Quetiapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev (1):CD006625
55. Kontaxakis VP, Ferentinos PP, Havaki-Kontaxaki BJ, Roukas DK (2005) Randomized controlled augmentation trials in clozapine-resistant schizophrenic patients: a critical review. Eur Psychiatry J Assoc Eur Psychiatrist 20:409-415 (Pubitemid 41318007)
56. Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV (2002) Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry 63:892-909 (Pubitemid 35231730)
57. Leucht S, Pitschel-Walz G, Abraham D, Kissling W (1999) Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr Res 35:51-68 (Pubitemid 29023554)
58. Leucht S, Komossa K, Rummel-Kluge C, Corves C, Hunger H, Schmid F, Asenjo Lobos C, Schwarz S, Davis JM (2009) A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry 166:152-163
59. Leucht S, Heres S, Kissling W, Davis JM (2011) Evidence-based pharmacotherapy of schizophrenia. Int J Neuropsychopharmacol 14:269-284
60. Leucht S, Hierl S, Kissling W, Dold M, Davis JM (2012a) Putting the efficacy of psychiatric and general medicine medication into perspective: review of meta-analyses. Br J Psychiatry 200:97-106
61. Leucht S, Tardy M, Komossa K, Heres S, Kissling W, Salanti G, Davis JM (2012b) Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet 379:2063-2071
62. Lieberman J, Pollack S, Lesser M, Kane J (1988) Pharmacologic characterization of tardive dyskinesia. J Clin Psychopharmacol 8:254-260
63. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353:1209-1223 (Pubitemid 41345943)
64. Lublin H, Haug HJ, Koponen H, Sigmundsson T, Kolb SA (2009) Ziprasidone versus olanzapine, risperidone or quetiapine in patients with chronic schizophrenia: a 12-week open-label, multicentre clinical trial. World J Biol Psychiatry 10:710-718
65. Luft B, Taylor D (2006) A review of atypical antipsychotic drugs versus conventional medication in schizophrenia. Expert Opin Pharmacother 7:1739-1748
66. Marwaha S, Johnson S, Bebbington P, Stafford M, Angermeyer MC, Brugha T, Azorin JM, Kilian R, Hansen K, Toumi M (2007) Rates and correlates of employment in people with schizophrenia in the UK, France and Germany. Br J Psychiatry 191:30-37 (Pubitemid 47035178)
67. McDonagh M, Peterson K, Carson S, Fu R, Thakurta S (2010) Drug class review: atypical antipsychotic drugs: Final Update 3 Report [Internet] Drug Class Reviews, Portland (OR)
68. McEvoy JP, Lieberman JA, Stroup TS, Davis SM, Meltzer HY, Rosenheck RA, Swartz MS, Perkins DO, Keefe RS, Davis CE, Severe J, Hsiao JK (2006) Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 163:600-610 (Pubitemid 44464569)
69. McQuade RD, Stock E, Marcus R, Jody D, Gharbia NA, Vanveggel S, Archibald D, Carson WH (2004) A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study. J Clin Psychiatry 65(Suppl 18):47-56
70. Meltzer HY, Massey BW (2011) The role of serotonin receptors in the action of atypical antipsychotic drugs. Curr Opin Pharmacol 11:59-67
71. Meltzer HY, Alphs L, Green AI, Altamura AC, Anand R, Bertoldi A, Bourgeois M, Chouinard G, Islam MZ, Kane J, Krishnan R, Lindenmayer JP, Potkin S (2003) Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry 60:82-91 (Pubitemid 36070868)
72. Meyer-Lindenberg A (2010) From maps to mechanisms through neuroimaging of schizophrenia. Nature 468:194-202
73. Möller HJ (2004) Non-neuroleptic approaches to treating negative symptoms in schizophrenia. Eur Arch Psychiatry Clin Neurosci 254:108-116
74. Mortimer A, Martin S, Loo H, Peuskens J (2004) A double-blind, randomized comparative trial of amisulpride versus olanzapine for 6 months in the treatment of schizophrenia. Int Clin Psychopharmacol 19:63-69 (Pubitemid 38316764)
75. Mortimer AM, Joyce E, Balasubramaniam K, Choudhary PC, Saleem PT (2007) Treatment with amisulpride and olanzapine improve neuropsychological function in schizophrenia. Hum Psychopharmacol 22:445-454 (Pubitemid 47611299)
76. Naber D, Riedel M, Klimke A, Vorbach EU, Lambert M, Kuhn KU, Bender S, Bandelow B, Lemmer W, Moritz S, Dittmann RW (2005) Randomized double blind comparison of olanzapine vs. clozapine on subjective well-being and clinical outcome in patients with schizophrenia. Acta Psychiatr Scand 111:106-115 (Pubitemid 40293177)
77. Osterberg L, Blaschke T (2005) Adherence to medication. N Engl J Med 353:487-497 (Pubitemid 41127293)
78. Peluso MJ, Lewis SW, Barnes TRE, Jones PB (2012) Extrapyramidal motor side-effects of first-and second-generation antipsychotic drugs. Br J Psychiatry 200:387-392
79. Peuskens J (1995) Risperidone in the treatment of patients with chronic schizophrenia: a multinational, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group. Br J Psychiatry 166:712-726, discussion 727-33
80. Peuskens J, Link CG (1997) A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia. Acta Psychiatr Scand 96:265-273 (Pubitemid 27428238)
81. Peuskens J, De Hert M, Mortimer A (2007) Metabolic control in patients with schizophrenia treated with amisulpride or olanzapine. Int Clin Psychopharmacol 22:145-152 (Pubitemid 46559870)
82. Potkin SG (2011) Asenapine: a clinical overview. J Clin Psychiatry 72(Suppl 1):14-18
83. Potvin S, Stip E, Lipp O, Elie R, Mancini-Marie A, Demers MF, Roy MA, Bouchard RH, Gendron A (2006) Quetiapine in patients with comorbid schizophrenia-spectrum and substance use disorders: an open-label trial. Curr Med Res Opin 22:1277-1285 (Pubitemid 44085579)
84. Puschner B, Born A, Giessler A, Helm H, Becker T, Angermeyer MC (2005) Effects of interventions to improve compliance with antipsychotic medication in people suffering from schizophrenia-results of recent reviews. Psychiatr Prax 32:62-67 (Pubitemid 40444743)
85. Rattehalli RD, Jayaram MB, Smith M (2010) Risperidone versus placebo for schizophrenia. Schizophr Bull 36:448-449
86. Robinson DG, Woerner MG, McMeniman M, Mendelowitz A, Bilder RM (2004) Symptomatic and functional recovery from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry 161:473-479 (Pubitemid 38326102)
87. Robinson DG, Woerner MG, Napolitano B, Patel RC, Sevy SM, Gunduz-Bruce H, Soto-Perello JM, Mendelowitz A, Khadivi A, Miller R, McCormack J, Lorell BS, Lesser ML, Schooler NR, Kane JM (2006) Randomized comparison of olanzapine versus risperidone for the treatment of first-episode schizophrenia: 4-month outcomes. Am J Psychiatry 163:2096-2102 (Pubitemid 46114229)
88. Rosenheck R, Chang S, Choe Y, Cramer J, Xu W, Thomas J, Henderson W, Charney D (2000) Medication continuation and compliance: a comparison of patients treated with clozapine and haloperidol. J Clin Psychiatry 61:382-386 (Pubitemid 30345942)
89. Ruhrmann S, Klosterkotter J, Bodatsch M, Bechdolf A, Schimmelmann BG, Nikolaides A, Hilboll D, Schultze-Lutter F (2012) Pharmacological prevention and treatment in clinical at-risk states for psychosis. Curr Pharm Des 18:550-557
90. Sacchetti E, Valsecchi P (2003) Quetiapine, clozapine, and olanzapine in the treatment of tardive dyskinesia induced by first-generation antipsychotics: a 124-week case report. Int Clin Psychopharmacol 18:357-359 (Pubitemid 38183490)
91. Saha S, Chant D, McGrath J (2007) A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch Gen Psychiatry 64:1123-1131 (Pubitemid 47529346)
92. Srisurapanont M, Maneeton B, Maneeton N (2004) Quetiapine for schizophrenia. Cochrane Database Syst Rev (2):CD000967
93. Stahl SM, Grady MM (2004) A critical review of atypical antipsychotic utilization: comparing monotherapy with polypharmacy and augmentation. Curr Med Chem 11:313-327 (Pubitemid 38240209)
94. Stroup TS, Lieberman JA, McEvoy JP, Swartz MS, Davis SM, Rosenheck RA, Perkins DO, Keefe RS, Davis CE, Severe J, Hsiao JK (2006) Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry 163:611-622 (Pubitemid 44464570)
95. Tarsy D, Lungu C, Baldessarini RJ (2011) Epidemiology of tardive dyskinesia before and during the era of modern antipsychotic drugs. Handb Clin Neurol 100:601-616
96. Tiihonen J, Lonnqvist J, Wahlbeck K, Klaukka T, Niskanen L, Tanskanen A, Haukka J (2009) 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 374:620-627
97. Tollefson GD, Birkett MA, Kiesler GM, Wood AJ (2001) Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine. Biol Psychiatry 49:52-63 (Pubitemid 32332954)
98. Tran PV, Hamilton SH, Kuntz AJ, Potvin JH, Andersen SW, Beasley C Jr, Tollefson GD (1997) Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 17:407-418 (Pubitemid 27414397)
99. Umbricht D, Kane JM (1995) Risperidone: efficacy and safety. Schizophr Bull 21:593-606
100. van Os J, Burns T, Cavallaro R, Leucht S, Peuskens J, Helldin L, Bernardo M, Arango C, Fleischhacker W, Lachaux B, Kane JM (2006) Standardized remission criteria in schizophrenia. Acta Psychiatr Scand 113:91-95 (Pubitemid 43348370)
101. Weiden PJ (2007) EPS profiles: the atypical antipsychotics are not all the same. J Psychiatr Pract 13:13-24 (Pubitemid 46148428)
102. Weinmann S, Read J, Aderhold V (2009) Influence of antipsychotics on mortality in schizophrenia: systematic review. Schizophr Res 113:1-11
103. Zhong KX, Sweitzer DE, Hamer RM, Lieberman JA (2006) Comparison of quetiapine and risperidone in the treatment of schizophrenia: A randomized, double-blind, flexible-dose, 8-week study. J Clin Psychiatry 67:1093-1103 (Pubitemid 44230881)